ROR2 Primary Antibody
|Aliases||BDB; BDB1; NTRKR2|
|Formulation||Purified antibody in PBS with 0.05% sodium azide.|
|Immunogen||Purified recombinant fragment of human ROR2 (AA: 59-155) expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Contact us to order
Figure 1: Western blot analysis using ROR2 mAb against human ROR2 (AA: 59-155) recombinant protein. (Expected MW is 36.8 kDa)
Figure 2: Western blot analysis using ROR2 mAb against HEK293 (1) and ROR2 (AA: 59-155)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 3: Flow cytometric analysis of Hela cells using ROR2 mouse mAb (green) and negative control (red).
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
|Description||The protein encoded by this gene is a receptor protein tyrosine kinase and type I transmembrane protein that belongs to the ROR subfamily of cell surface receptors. The protein may be involved in the early formation of the chondrocytes and may be required for cartilage and growth plate development. Mutations in this gene can cause brachydactyly type B, a skeletal disorder characterized by hypoplasia/aplasia of distal phalanges and nails. In addition, mutations in this gene can cause the autosomal recessive form of Robinow syndrome, which is characterized by skeletal dysplasia with generalized limb bone shortening, segmental defects of the spine, brachydactyly, and a dysmorphic facial appearance. |
|References (references)||1. Int J Cancer. 2013 Aug 15;133(4):779-87. |
2. Mol Cancer. 2010 Jun 30;9:170.